Skip to main content
SpringerLink
Log in

Hochmaligne Non-Hodgkin-Lymphome

  • Chapter
Therapiekonzepte Onkologie

Zusammenfassung

Häufigkeit und Inzidenz: Der Anteil hochmaligner Non-HodgkinLymphome (NHL) an der Gesamtzahl maligner Erkrankungen liegt bei ca. 2–3%, wobei die Häufigkeit der NHL stetig zunimmt. So stieg die jährliche Inzidenzrate in den USA von 1950–1989 von 5,9 auf 13,7 pro 100000 Einwohner. Die Ursachen dieser Entwicklung, die auch in Westeuropa zu beobachten ist, sind noch nicht geklärt [9, 83].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Brittinger G, Bartels H, Common H et al. (1984) Clinical and prognostic relevance of the Kiel dassification of non-Hodgkin lymphomas: results of a prospective multicenter study by the Kiel lymphoma study group. Hematol Oncol 2: 269–306

    Article  PubMed  CAS  Google Scholar 

  2. Cabanillas F, Hagemeister FB, Bodey GP et al. (1982) IMVP 16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 60: 693–697

    PubMed  CAS  Google Scholar 

  3. Coiffier B, Gisselbrecht C, Herbrecht R et al. (1989) LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 7: 1018–1026

    PubMed  CAS  Google Scholar 

  4. Coleman CN, Picozzi VJ, Cox RS et al. (1989) Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 4: 399–404

    Google Scholar 

  5. Coltman CA, Dahlberg S, Jones SE et al. (1988) Southwest Oncology Group Studies in diffuse large cell lymphoma: A subset analysis. In: Kimura K (ed) Cancer Chemotherapy: Challenges for the future, Tokyo: Excerpta Medica, 1988: 194–202

    Google Scholar 

  6. Connors JM, Klimo P, Fairy RN, Voss N (1987) Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann Int Med 107: 25–30

    Article  PubMed  CAS  Google Scholar 

  7. Connors JM, Klimo P (1988) MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations. Semin Hematol 25: 41–46

    PubMed  CAS  Google Scholar 

  8. De Bruin PC, Noorduyn AL, van der Valk P et al. (1993) Noncutaneous T-cell lymphomas. Recognition of a lymphoma type with a relatively favorable prognosis. Cancer 71: 2604–2612

    Article  PubMed  Google Scholar 

  9. Devesa SS, Fears T (1992) Non-Hodgkin-lymphoma time trends: United States and International Data. Cancer Res 52: 5432–5440

    Google Scholar 

  10. DeVita VT Jr, Jaffe ES, Hellman S (1985) Hodgkin’s disease and the non-Hodgkin’s lymphomas. In: Cancer-principles and practice of oncology (eds: DeVita VT, Hellman S, Rosenberg SA). JB Lippincott Company: 1623–1709

    Google Scholar 

  11. Dhaliwal HS, Rohatiner AZS, Gregory W et al. (1993) Combination chemotherapy for intermediate and high grade non-Hodgkin’s lymphoma. Br J Cancer 68: 767–774

    Article  PubMed  CAS  Google Scholar 

  12. Dixon DO, Neilan B, Jones SE et al. (1986) Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 4: 295–305

    PubMed  CAS  Google Scholar 

  13. Doglioni C, Wotherspoon AC, Moschini A et al. (1992) High incidence of primary gastric lymphoma in northeastern Italy. Lancet 339: 834–835

    Article  PubMed  CAS  Google Scholar 

  14. Engelhard M, Meusers P, Brittinger G et al. (1991) Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin’s lymphomas: Updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy. Ann Oncol 2 (Suppl 2): 177–180

    Article  PubMed  Google Scholar 

  15. Engert A, Engelhard M, Scheulen M, Baltes-Engler S et al. (1993) Phase-II study of idarubicin, ifosfamide, and VP-16 (IIVP-16) in patients with relapsed aggressive non-Hodgkin’s lymphoma. Ann Hematol 67 (Suppl): A 30 [Ann Oncol 1994 submitted]

    Google Scholar 

  16. Filipovich AH, Mathur A, Kamat D, Shapiro RS (1992) Primary immunodeficiencies: Genetic risk factors for lymphoma. Cancer Res 52 (Suppl): 5465–5467

    Google Scholar 

  17. Fisher RI, Gaynor ER, Dahlberg S et al. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328: 1002–1006

    Article  PubMed  CAS  Google Scholar 

  18. Gerhartz HH, Engelhard M, Brittinger G et al. (1993) Randomized, double-blind, placebo-controled phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin’s lymphomas. Blood 82: 2329–2339

    PubMed  CAS  Google Scholar 

  19. Gisselbrecht C, Bosly A, Lepage E et al. (1993) Autologous hematopoietic stem cell transplantation in intermediate and high grade non-Hodgkin’s lymphoma: a review. Ann Oncol 4 (Suppl 1): 7–13

    Article  PubMed  Google Scholar 

  20. Gobbi PG, Diongi P, Barbieri F et al. (1990) The role of surgery in the multimodal treatment of primary gastric non-Hodgkin’s lymphomas. A report of 76 cases and review of the literature. Cancer 65: 2528–2536

    Article  PubMed  CAS  Google Scholar 

  21. Gordon LI, Harrington D, Andersen J et al. (1992) Comparison of a second generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin’s lymphoma. N Engl J Med 327: 1342–1349

    Article  PubMed  CAS  Google Scholar 

  22. Grogan L, Corbally N, Dervan PA et al. (1994) Comparable prognostic factors and survival in elderly patients with aggressive non-Hodgkin’s lymphoma treated with standard-dose adriamycin-based regimens. Ann Oncol 5 (Suppl l): 47–51

    Article  PubMed  Google Scholar 

  23. Grossbard ML, Lambert JM, Goldmacher VS et al. (1993) Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 11: 726–737

    PubMed  CAS  Google Scholar 

  24. Haioun C, Lepage E, Gisselbrecht C et al. (1992) Autologous bone marrow transplantation versus sequential chemotherapy in first complete remission aggressive non-Hodgkin’s lymphoma: 1st interim analysis on 370 patients (LNH-87 protocol). Proc Am Soc Clin Oncol 11: 316 (abstr)

    Google Scholar 

  25. Harris NL, Jaffe ES, Stein H et al. (1994) A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361–1392

    Google Scholar 

  26. Hoelzer D, Thiel E, Löffler H et al. (1984) Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood 64: 38–47

    PubMed  CAS  Google Scholar 

  27. Jones SE, Müller TP, Connors JM (1989) Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. J Clin Oncol 7: 1186–1191

    PubMed  CAS  Google Scholar 

  28. Kadin ME (1994) Primary Ki-1-positive anaplastic large-cell lymphoma: A distinct clinicopathologic entity. Ann Oncol 5 (Suppl 1): 25–30

    Article  PubMed  Google Scholar 

  29. Kath R, Höffken K, Günzel K et al. (1990) Chemotherapie des nicht-endemischen Burkitt-Lymphoms. Dtsch med Wschr 115: 1219–1226

    Article  PubMed  CAS  Google Scholar 

  30. Köppler H, Pflüger KH, Eschenbach I et al. (1994) Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin’s lymphomas: Treatment results and prognostic risk factors analysis in a multi-centre trial. Ann Oncol 5: 49–55

    Article  PubMed  Google Scholar 

  31. Kwak L, Olshen R, Halpern J et al. (1988) Dose intensity: relationship to prognostic factors for diffuse large cell lymphoma. Proc Am Soc Clin Oncol 7: 226 (abstr)

    Google Scholar 

  32. Lee KA, Finnegan MC, Sheridan E et al. (1994) Analysis of the p53 gene, its expression and protein stabilization in non-Hodgkin’s lymphomas. Annals of Oncology 5: 85–88

    Article  PubMed  Google Scholar 

  33. Lepage E, Gisselbrecht C, Haioun C et al. (1992) Relative received dose intensity (DI) in poor risk lymphoma patients: Higher DI correlates with longer survival. A study from GELA. Blood 80 (Suppl 1 ): 158 (abstr 621)

    Google Scholar 

  34. Lennert K, Feller AC (1990) Histopathologie der Non-Hodgkin-Lymphome. Springer Verlag

    Google Scholar 

  35. Liang R, Todd D, Chan TK et al. (1993) COPP chemotherapy for elderly patients with intermediate and high grade non-Hodgkin’s lymphoma. Hematol Oncol 11:43 —50

    Google Scholar 

  36. Longo DL, DeVita VT, Duffey PL et al. (1991) Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol 9: 25–38

    PubMed  CAS  Google Scholar 

  37. Maksymiuk AW, Bratvold JS, Ezzat W et al. (1993) Non-Hodgkin’s-Lymphoma in Saskatchewan — a review of 10 years’ experience. Cancer 73: 711–719

    Article  Google Scholar 

  38. Magrath I (1992) Molecular basis of lymphomagenesis. Cancer Research 52 (Suppl): 5529–5540

    Google Scholar 

  39. Maor MH, Velasquez WS, Fuller LM, Silvermintz KB (1990) Stomach conservation in stages IE and IIE gastric non-Hodgkin’s lymphoma. J Clin Oncol 8: 266–271

    PubMed  CAS  Google Scholar 

  40. McKelvey EM, Gottlieb JA, Wilson HE et al. (1976) Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38: 1484–1493

    Article  PubMed  CAS  Google Scholar 

  41. McMaster ML, Johnson DH, Greer JP et al. (1991) A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin’s lymphoma. Cancer 67: 1487–1492

    Article  PubMed  CAS  Google Scholar 

  42. Meyer RM, Hryniuk WM, Goodyear MGE (1991) The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin’s lymphoma. J Clin Oncol 9: 339–347

    PubMed  CAS  Google Scholar 

  43. Meyer RM, Quirt IC, Skillings JR et al. (1993) Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin’s lymphoma. N Engl J Med, 329: 1770–1776

    Article  PubMed  CAS  Google Scholar 

  44. Miller TP, Grogan TM, Dalton WS et al. (1991) P-glycoprotein expression in malignant lymphoma and reversal of dinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9: 17–24

    PubMed  CAS  Google Scholar 

  45. Milpied N, Ifrah N, Kuentz M et al. (1989) Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remisson. Br J Haematol 73: 82–87

    Article  PubMed  CAS  Google Scholar 

  46. Montserrat E, Garcia-Conde, Vinolas N, Estapé J (1991) ProMACE-CytaBOM vs. CHOP in the treatment of unfavorable lymphomas: a randomized trial. Blood 78 (Suppl 1): 127a

    Google Scholar 

  47. Morel P, Lepage E, Brice P et al. (1992) Prognosis and treatment of lymphoblastic lymphoma in adults: a report of 80 patients. J Clin Oncol 10 (7): 1078–1085

    PubMed  CAS  Google Scholar 

  48. Niehans GA, Jaszcz W, Brunetto V et al. (1992) Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas. Cancer Res 52: 3768–3775

    PubMed  CAS  Google Scholar 

  49. Nissen NI, Ersboll J, Hansen HS et al. (1983) A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I—II non-Hodgkin’s lymphomas. Cancer 52: 1–7

    Article  PubMed  CAS  Google Scholar 

  50. Nouwrousian MR, Mengelkoch B, Kleine-Herzbruch R et al. (1993) Intensified sequential combination chemotherapy (CEBOPP/VIML), G-CSF and radiation in patients with high grade malignant non-Hodgkin’s lymphoma (NHL). Ann Hematol 67 (Suppl): A88

    Google Scholar 

  51. O’Connel MJ, Anderson J, Earle JD et al. (1984) Combined modality therapy of advanced unfavorable non-Hodgkin’s lymphoma (NHL). An ECOG randomized clinical trial. Proc Amer Soc Onc 241

    Google Scholar 

  52. Offit K, Lo Coco F, Louie DC et al. (1994) Rearrangement of the bd-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med 331: 74–80

    Article  PubMed  CAS  Google Scholar 

  53. O’Reilly S, Klimo P, Connors JM et al. (1991) Low-dose ACOP-B and VABE: weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma. J Clin Oncol 9: 741–747

    PubMed  Google Scholar 

  54. Ostermann B, Jonsson H, Tavelin B, Lenner P (1993) Non-Hodgkin’s lymphoma in northern Sweden. Acta Oncologica 32: 507–516

    Article  Google Scholar 

  55. Parker BA, Santarelli M, Green MR et al. (1993) AMOPLACE treatment of intermediate and high-grade malignant lymphoma: a cancer and leukemia group B study. J Clin Oncol 11: 248–254

    PubMed  CAS  Google Scholar 

  56. Pettengel R, Gurney H, Radford JA et al. (1992) Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial. Blood 80: 1430–1436

    Google Scholar 

  57. Philip T, Guglielmi C, Hagenbeek A et al. (1992) The PARMA international randomized prospective study in relapsed non Hodgkin lymphoma: Second interim analysis of 172 patients. Blood 80 (Suppl 1): 67 (abstr)

    Google Scholar 

  58. Sack H, Budach V, Stuschke M, Hoederat A (1992) Non-Hodgkin lymphomas (NHL) — Early stages: Interim results of a multi-centre trial. Cancer Res Clin Oncol 118 (Suppl): R115

    Google Scholar 

  59. Salles G, Shipp MA, Coiffier B (1994) Chemotherapy of non-Hodgkin’s aggressive lymphomas. Semin Hematol 31: 46–69

    PubMed  CAS  Google Scholar 

  60. Santini G, Congui AM, Coser P et al. (1991) Autologous bone marrow transplantation for advanced stage adult lymphoblastic lymphoma in first CR: A study of the NHLGSG. Leukemia 5 (Suppl 1): 42–45

    PubMed  Google Scholar 

  61. Scherr PA, Hutchinson GB, Neiman RS (1992) Non-Hodgkin’s lymphoma and occupational exposure. Cancer Res 52 (Suppl): 5503–5509

    Google Scholar 

  62. Shapiro RS, McClain K, Frizzera G et al. (1988) Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 71: 1234–1243

    PubMed  CAS  Google Scholar 

  63. Shipp MA, Klatt MM, Yeap B et al. (1989) Patterns of relapse in large-cell lymphoma patients with bulk disease: implications for the use of the adjuvant radiation therapy. J Clin Oncol 7: 613–618

    PubMed  CAS  Google Scholar 

  64. Shipp MA, Yeap BY, Harrington DP et al. (1990) The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol 8: 84–93

    PubMed  CAS  Google Scholar 

  65. Slater DE, Mertelsmann R, Kaziner B et al. (1986) Lymphoblastic lymphoma in adults. J Clin Oncol 4: 57–67

    PubMed  CAS  Google Scholar 

  66. Solal-Celigny P, Chastang C, Herrera A et al. (1987) The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin’s lymphoma. J Clin Oncol 6: 1838–1844

    Google Scholar 

  67. Somers R, Carde P, Thomas J et al. (1994) EORTC study of non-Hodgkin’s lymphoma: Phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate and high grade lymphoma. Ann Oncol 5 (Suppl 2): 85–89

    Article  PubMed  Google Scholar 

  68. Sonneveld P, Michiels JJ (1990) Full dose chemotherapy in elderly patients with non-Hodgkin’s lymphoma: a feasibility study using a mitoxantrone containing regimen. Br J Cancer 62: 105–108

    Article  PubMed  CAS  Google Scholar 

  69. Stansfield AG, Diebold J, Kapanci Y et al. (1988) Updated Kiel classification for lymphomas. The Lancet: 292–293

    Google Scholar 

  70. Steinke B, Buss K, Reinold H-M (1992) Cyclic alternating chemotherapy of high-grade malignant non-Hodgkin’s lymphomas with VIM-Bleo and CHOP. Eur J Cancer 28: 100–104

    Article  PubMed  CAS  Google Scholar 

  71. Taal BG, den Hartog Jager FCA, Burgers JMV et al. (1989) Primary non-Hodgkin’s lymphoma of the stomach: changing aspects and therapeutic choices. Eur J Cancer Clin Oncol 25: 439–450

    Article  PubMed  CAS  Google Scholar 

  72. The International Non-Hodgkin’s lymphoma prognostic factors project (1993) A predictive model for aggressive Non-Hodgkin’s-lymphoma. N Engl J Med 329: 987–949

    Article  Google Scholar 

  73. Tigaud J-D, Demolombe S, Bastion Y et al. (1991) Ifosfamide continuous infusion plus etoposide in the treatment of elderly patients with aggressive lymphoma: a phase II study. Hematol Oncol 9: 225–233

    Article  PubMed  CAS  Google Scholar 

  74. Tirelli U, Zagonel V, Errante D et al. (1992) A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin’s lymphoma. J Clin Oncol 10: 228–236

    PubMed  CAS  Google Scholar 

  75. Tondini C, Zanini M, Lombardi F et al. (1993) Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I and II histologically aggressive non-Hodgkin’s lymphomas. J Clin Oncol 11: 720–725

    PubMed  CAS  Google Scholar 

  76. Trümper L, Renner Ch, Nahler M et al. (1994) Intensification of the CHOEP regimen for high grade non-Hodgkin’s lymphoma by G-CSF: Feasibility of a 14-day regimen. Onkologie 17: 69–71

    Article  Google Scholar 

  77. Tura S, Zinzani PL, Mazza P et al. (1992) ABMT vs. DHAP in residual disease following third generation regimens for aggressive non-Hodgkin’s lymphoma. Blood 80 (Supp 1 ): 157 (Abstr)

    Google Scholar 

  78. Velasquez WS, Cabanillas F, Salvadore P et al. (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high dose AraC and dexamethasone (DHAP). Blood 71: 117–122

    PubMed  CAS  Google Scholar 

  79. Velasquez WS, Hagemeister F, McLaughlin P et al. (1992) E-SHAP: An effective treatment for refractory and relapsing lymphoma. A long follow-up. Proc Am Soc Clin Oncol 11: 326 (Abstr 1111)

    Google Scholar 

  80. Vitetta ES, Stone M, Amlot P et al. (1991) Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 51: 4052–4058

    PubMed  CAS  Google Scholar 

  81. Vose JM, Armitage JO, Weisenburger DD et al. (1988) The importance of age in survival of patients treated with chemotherapy for agressive non-Hodgkin’s lymphoma. J Clin Oncol 6: 1838–1844

    PubMed  CAS  Google Scholar 

  82. Weick JK, Dahlberg S, Fisher RIO et al. (1991) Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin’s lymphoma with MACOP-B: a southwest oncology group study. J Clin Oncol 9: 748–753

    PubMed  CAS  Google Scholar 

  83. Weisenburger DD (1994) Epidemiology of non-Hodgkin’s lymphoma: Recent findings regarding an emerging epidemic. Ann Oncol 5 (Suppl 1): 19–24

    Article  PubMed  Google Scholar 

  84. Yano T, van Krieken JHJM, Magrath IT et al. (1992) Histogenetic correlations between subcategories of small noncleaved cell lymphomas. Blood 79: 1282–1290

    PubMed  CAS  Google Scholar 

  85. Yunis JJ, Mayer MG, Arnesen MA et al. (1989) Bd-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med 320: 1047–1054

    Article  PubMed  CAS  Google Scholar 

  86. Zahm SH, Blair A (1992) Pesticides and Non-Hodgkin’s lymphoma. Cancer Res 52 (Suppl): 5485–5488

    Google Scholar 

  87. Ziegler JL (1981) Burkitt’s lymphoma. N Engl J Med 305: 735–745

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. G. Trenn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Engelhard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Brittinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung) Westdeutsches Tumorzentrum Essen, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Siegfried Seeber  & Jochen Schütte  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Trenn, G., Engelhard, M., Brittinger, G. (1995). Hochmaligne Non-Hodgkin-Lymphome. In: Seeber, S., Schütte, J. (eds) Therapiekonzepte Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10494-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10494-1_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-58586-2

  • Online ISBN: 978-3-662-10494-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation